1. Home
  2. RARE
  3. RARE News

Latest Ultragenyx Pharmaceutical Inc. (RARE) News on September 15, 2025

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
RARE

Zacks

5 days ago

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

RARE Reports Positive Long-Term Data From Metabolic Disorder Study
RARE

Zacks

6 days ago

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

RARE

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Friday

RARE

MT Newswires

3 months ago

Sector Update: Health Care

RARE

MT Newswires

3 months ago

Ultragenyx Says GTX-102 Granted FDA Breakthrough Therapy Status to Treat Angelman Syndrome

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
RARE

GlobeNewswire

3 months ago

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

3 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
RARE

GlobeNewswire

3 months ago

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

RARE

MT Newswires

4 months ago

William Blair Initiates Ultragenyx Pharmaceutical at Outperform

3 High Growth Tech Stocks In The US Market
RARE

Simply Wall St.

4 months ago

3 High Growth Tech Stocks In The US Market

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

4 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
RARE

GlobeNewswire

4 months ago

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
RARE

Simply Wall St.

4 months ago

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Ultragenyx price target lowered to $100 from $140 at Truist
RARE

TipRanks

4 months ago

Ultragenyx price target lowered to $100 from $140 at Truist

Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
RARE

Simply Wall St.

4 months ago

Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
RARE

GlobeNewswire

4 months ago

Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference

RARE

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE

Zacks

4 months ago

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y

Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
RARE

GuruFocus.com

4 months ago

Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
RARE

GlobeNewswire

4 months ago

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
RARE

GlobeNewswire

4 months ago

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

5 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

5 months ago

BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating

Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential
RARE

Insider Monkey

5 months ago

Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy
RARE

Insider Monkey

6 months ago

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

6 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx price target lowered to $115 from $140 at Piper Sandler
RARE

TipRanks

6 months ago

Ultragenyx price target lowered to $115 from $140 at Piper Sandler

Ultragenyx to Participate at Investor Conferences in March
RARE

GlobeNewswire

7 months ago

Ultragenyx to Participate at Investor Conferences in March

Exploring Three High Growth Tech Stocks in the United States
RARE

Simply Wall St.

7 months ago

Exploring Three High Growth Tech Stocks in the United States

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

7 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

7 months ago

Ultragenyx Pharmaceutical Eyes Aug. 18 FDA Approval for Sanfilippo Syndrome Gene Therapy Treatment

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

7 months ago

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
RARE

Simply Wall St.

7 months ago

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

RARE

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE

Zacks

7 months ago

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
RARE

GuruFocus.com

7 months ago

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

RARE

MT Newswires

7 months ago

Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises

RARE

Associated Press Finance

7 months ago

Ultragenyx: Q4 Earnings Snapshot

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

7 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

7 months ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
RARE

Zacks

7 months ago

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study

Ultragenyx announces new data on UX111 AV gene therapy
RARE

TipRanks

7 months ago

Ultragenyx announces new data on UX111 AV gene therapy

RARE

MT Newswires

7 months ago

Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
RARE

GlobeNewswire

7 months ago

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

RARE

MT Newswires

8 months ago

Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $47 From $48, Keeps Neutral Rating

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

8 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential
RARE

Insider Monkey

8 months ago

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
RARE

Benzinga

8 months ago

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
RARE

GlobeNewswire

8 months ago

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
RARE

Zacks

8 months ago

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RARE

GlobeNewswire

8 months ago

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
RARE

Pharmaceutical Technology

8 months ago

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
RARE

GlobeNewswire

8 months ago

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

RARE

MT Newswires

8 months ago

Ultragenyx Pharmaceutical Insider Sold Shares Worth $495,231, According to a Recent SEC Filing

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

9 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
RARE

Zacks

9 months ago

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
RARE

GlobeNewswire

9 months ago

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

RARE

MT Newswires

9 months ago

Ultragenyx Reports Patient Dosing in Angelman Syndrome Trial

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
RARE

GlobeNewswire

9 months ago

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

RARE

MT Newswires

9 months ago

Ultragenyx Seeks FDA Accelerated Approval for Gene Therapy to Treat Sanfilippo Syndrome

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

9 months ago

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx to Participate in Investor Conferences in December
RARE

GlobeNewswire

10 months ago

Ultragenyx to Participate in Investor Conferences in December

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

10 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
RARE

GlobeNewswire

10 months ago

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations
RARE

Simply Wall St.

10 months ago

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
RARE

Zacks

10 months ago

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...
RARE

GuruFocus.com

10 months ago

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...

RARE

MT Newswires

10 months ago

Ultragenyx Pharmaceutical Q3 Net Loss Narrows, Revenue Rises; Shares Fall After Hours

RARE

Associated Press Finance

10 months ago

Ultragenyx: Q3 Earnings Snapshot

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

10 months ago

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
RARE

Insider Monkey

10 months ago

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

a year ago

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year
RARE

Simply Wall St.

a year ago

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a year ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/15/2024

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
RARE

Zacks

a year ago

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag

RARE

MT Newswires

a year ago

Ultragenyx's Setrusumab Receives FDA Breakthrough Therapy Designation

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
RARE

GlobeNewswire

a year ago

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

RARE's Wilson Disease Candidate Betters Standard Therapy in Study
RARE

Zacks

a year ago

RARE's Wilson Disease Candidate Betters Standard Therapy in Study

RARE

MT Newswires

a year ago

Ultragenyx Pharmaceutical Wilson Disease Therapy Study Shows Meaningful Data

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
RARE

GlobeNewswire

a year ago

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
RARE

GlobeNewswire

a year ago

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a year ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

a year ago

Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,117,000, According to a Recent SEC Filing

Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
RARE

Insider Monkey

a year ago

Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Ultragenyx to Participate in Investor Conferences in September
RARE

GlobeNewswire

a year ago

Ultragenyx to Participate in Investor Conferences in September

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a year ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

a year ago

Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,003,400, According to a Recent SEC Filing

RARE

MT Newswires

a year ago

Wedbush Adjusts Ultragenyx Pharmaceutical's PT to $46 From $43, Keeps Neutral Rating

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
RARE

Zacks

a year ago

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

RARE

Associated Press Finance

a year ago

Ultragenyx: Q2 Earnings Snapshot

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

a year ago

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

a year ago

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
RARE

GlobeNewswire

a year ago

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
RARE

Investor's Business Daily

a year ago

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a year ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
RARE

Zacks

a year ago

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans

RARE

MT Newswires

a year ago

Ultragenyx Reports 'Successful' End-of-Phase 2 FDA Meeting For Angelman Syndrome Program

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
RARE

GlobeNewswire

a year ago

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a year ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Share on Social Networks: